Timdarpacept is named as an intervention in 2 current clinical trials in our China and Japan registers. 1 is recruiting patients now. The most common phase is Phase 1/2. The lead sponsor is ImmuneOnco Biopharmaceuticals (Shanghai) Inc. The most-studied condition is Advanced Solid Tumors.
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL5314779, CC BY-SA 3.0. The Guide to Pharmacology has no record of this medicine, so its targets rest on ChEMBL alone. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
IMM01+Azacitidine VS Placebo +Azacitidine in Patients With Newly Diagnosed Chronic Myelomonocytic Leukemia (CMML1-2)
NCT06647862 · ClinicalTrials.gov ↗ · Chronic Myelomonocytic Leukemia
|
Phase 3 | Recruiting | ImmuneOnco Biopharmaceuticals (Shanghai) Inc | China, Japan |
|
A Study of IMM2510 + IMM01 Combination Therapy in Patients With Advanced Solid Tumors
NCT07170787 · ClinicalTrials.gov ↗ · Advanced Solid Tumors
|
Phase 1/2 | Not yet open | ImmuneOnco Biopharmaceuticals (Shanghai) Inc | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| ImmuneOnco Biopharmaceuticals (Shanghai) Inc | 2 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 2 | 1 |
| Clinical trials in Japan | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our China and Japan registers name Timdarpacept (also registered as IMM01) as a drug or biological intervention, as of the registry sync on 1 October 2026. Completed and withdrawn studies are not counted.
Yes. 1 of the 2 trials is recruiting: 1 with sites in China and 1 with sites in Japan. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
The lead sponsor is ImmuneOnco Biopharmaceuticals (Shanghai) Inc. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Timdarpacept works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Timdarpacept works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Timdarpacept (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 1 Oct 2026. How every register is built: methodology · fixes we have made: corrections log.